Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell Carcinoma
Phase II trial of nivolumab in 120 treatment naive patients with ccRCC.
Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma
- ClinicalTrials.gov Identifier: NCT03117309
- Protocol Number: 17-508
- Principal Investigator: David McDermott
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required